Centre National De La Recherche Scientifique

Université De Technologie De Compiègne

Gradient Inc.

Berangere Avalle-Bihan

Alain Friboulet

Daniel Thomas

Hassan Isber

Severine Padiolleau

Claire Loussouarn

Helene Debat

Provided is a composition of matter binding specifically to STAT5, preferably to STAT5B, including a nucleic acid aptamer, and methods of treatment of cancer, and in particular leukaemia via the inhibition of STAT5 protein. The present invention relates more particularly to specific aptamers of STAT5 protein, and the therapeutic or diagnostic use thereof. Also provided is a method for detecting STAT5 in a biological sample, including contacting a nucleic acid aptamer binding specifically to STAT5 with a sample taken beforehand from a subject and determining the quantity of said aptamer bound to said sample.

STAT5 inhibitors and use thereof

The invention concerns novel compounds capable of modulating the activity and stimulating the production of catalytic antibodies. More particularly, the invention concerns a compound capable of increasing the activity of an antibody having specific affinity for the catalytic site of the antibody, and it is not immunogenic. Such compounds are useful in particular for therapeutic treatment or prevention of a pathology related to an enzymatic deficiency, to stimulate in vivo hydrolysis of xenobiotics, drugs, medicines or any other molecule potentially toxic for the organism or for preventing or inhibiting allergic reactions.

Compounds capable of modulating the activity and stimulating the production of a catalytic antibody

Growing community of inventors

Compiegne, France

Berangere Avalle-Bihan